IM Cannabis (NASDAQ:IMCC) Releases Quarterly Earnings Results
by Kim Johansen · The Markets DailyIM Cannabis (NASDAQ:IMCC – Get Free Report) issued its quarterly earnings results on Monday. The company reported ($0.86) EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.95), Zacks reports. The firm had revenue of $11.25 million for the quarter, compared to analysts’ expectations of $15.66 million. IM Cannabis had a negative return on equity of 301.99% and a negative net margin of 21.24%.
IM Cannabis Stock Performance
IM Cannabis stock opened at $0.37 on Wednesday. The firm has a market capitalization of $2.18 million, a P/E ratio of -0.26 and a beta of 2.17. The stock has a fifty day moving average price of $0.93 and a 200 day moving average price of $1.38. IM Cannabis has a 52 week low of $0.30 and a 52 week high of $7.12. The company has a current ratio of 0.82, a quick ratio of 0.56 and a debt-to-equity ratio of 0.25.
Analyst Ratings Changes
Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of IM Cannabis in a research note on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has an average rating of “Sell”.
View Our Latest Research Report on IMCC
Institutional Trading of IM Cannabis
An institutional investor recently bought a new position in IM Cannabis stock. DRW Securities LLC acquired a new stake in shares of IM Cannabis Corp. (NASDAQ:IMCC – Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 23,060 shares of the company’s stock, valued at approximately $32,000. DRW Securities LLC owned about 0.39% of IM Cannabis at the end of the most recent reporting period. Institutional investors and hedge funds own 7.68% of the company’s stock.
IM Cannabis Company Profile
IM Cannabis Corp is a vertically integrated medical cannabis company based in Israel, specializing in the research, cultivation and production of cannabis-based formulations. The company holds three key licenses granted by the Israeli Ministry of Health, covering cultivation, possession and distribution of medical-grade cannabis. Its production facilities in Moshav Yizrael feature controlled-environment agriculture chambers designed to deliver consistent, high-purity cannabinoid profiles.
The company’s product portfolio includes standardized cannabis oils, distillates, vaporizer cartridges and topical preparations, all formulated under Good Manufacturing Practice (GMP) standards.